Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.
Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.
In the United States, people over 50 are often stereotyped as complacent, set in their ways and extremely loyal to their preferred brands, but a new study released Tuesday by Ketchum found that the opposite is true.
CDM New York populated this engaging and outstanding website for Salix with unique visuals and messaging elements designed to drive awareness.
In this sponsored podcast, MM&M's Larry Dobrow speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.
Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny
In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit
Executives attending Cannes Lions Health weigh in on the imbalance seen in the U.S. between branded and unbranded drug ads.
A rundown of MM&M at Cannes, and five burning questions heading into the Lions Health festival and awards.
If you truly understand who your high writers and compliant patients are, you'll understand when and how to communicate with prospects that look and act like them.
Pharma marketers are wondering if these exorbitant media buys ($4.9 million for 30 seconds) were worth the investment for Valeant and AstraZeneca. Was either strategy successful?
IPG's McCann Health announces branding and operational changes aimed at integrating its US and Canadian shops.
Dr. Reddy's is blocked from selling generic purple Nexium; the FDA approves Roche's melanoma drug; Novartis says Entresto keeps heart-failure patients from being readmitted to the hospital
We're not out to reinvent the wheel if we don't have to but we will need to localize the campaign for New Zealand and do what is right for our physicians and our patients.
Pharma has hidden behind the ability to turn commenting off on Facebook pages, allowing marketers to use the channel much as they would a typical web page.
The second annual Lions Health creativity festival ended Saturday.
Moore, a longtime Goodwill Ambassador for Unicef, talked with MM&M about how creativity can be used to improve public health.
Either we need to stop calling it digital marketing (because digital is baked into business) and just consider it marketing. If we feel like we can't, then digital might very well be a dead-end job.
Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.
Bridgette Heller, Merck EVP and president of its consumer care division, adjured life-sci managers to enable women to unleash the full power of their knowledge and ideas to drive growth in the business.
Physician trust in pharmaceutical brands is driven by an emotional connection as well as functional attributes and perceptions of the manufacturer, said Harris Interactive, which found Advair, Spiriva and Mirena to be tops in their categories with doctors.
Hologic alleges KV has botched the marketing and wants rights to the drug. KV disagrees.
A government-funded study looks at whether patients with breast cancer really need 12 months of the treatment.
Sales of Teva's MS blockbuster Copaxone are likely to peak this year before giving way as more therapeutic options become available, a Teva exec says.
Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.
The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.
GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.
Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that's having an impact on promotional spend.
- BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Wednesday, December 7, 2016
- Five things for pharma marketers to know: Monday, December 5, 2016
- Matt Brown leaves Guidemark Health after merger falls through
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Women in senior industry roles improve connections with patients, execs say